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Is lymphovascular invasion a 
powerful predictor for biochemical 
recurrence in pT3 N0 prostate 
cancer? Results from the K-CaP 
database
Yong Hyun Park1, Yejin Kim2, Hwanjo Yu2, In Young Choi3, Seok-Soo Byun4, Cheol Kwak5, 
Byung Ha Chung6, Hyun Moo Lee7, Choung Soo Kim8 & Ji Youl Lee1
To assess the impact of lymphovascular invasion (LVI) on the risk of biochemical recurrence (BCR) in pT3 
N0 prostate cancer, clinical data were extracted from 1,622 patients with pT3 N0 prostate cancer from 
the K-CaP database. Patients with neoadjuvant androgen deprivation therapy (n = 325) or insufficient 
pathologic or follow-up data (n = 87) were excluded. The primary endpoint was the oncologic 
importance of LVI, and the secondary endpoint was the hierarchical relationships for estimating BCR 
between the evaluated variables. LVI was noted in 260 patients (21.5%) and was significantly associated 
with other adverse clinicopathologic features. In the multivariate Cox regression analysis, LVI was 
significantly associated with an increased risk of BCR after adjusting for known prognostic factors. In 
the Bayesian belief network analysis, LVI and pathologic Gleason score were found to be first-degree 
associates of BCR, whereas prostate-specific antigen (PSA) level, seminal vesicle invasion, perineural 
invasion, and high-grade prostatic intraepithelial neoplasia were considered second-degree associates. 
In the random survival forest, pathologic Gleason score, LVI, and PSA level were three most important 
variables in determining BCR of patients with pT3 N0 prostate cancer. In conclusion, LVI is one of the 
most powerful adverse prognostic factors for BCR in patients with pT3 N0 prostate cancer.
Prostate cancer is the most common newly diagnosed cancer in males, and the second most common cause of 
cancer-related death in the United States1. Approximately 25–50% of patients undergoing radical prostatectomy 
harbor extracapsular disease2, which is associated with an increased risk of biochemical recurrence (BCR)3,4. 
Recently published studies have demonstrated that adjuvant treatment for selected patients can reduce the risk 
of BCR5,6; however, there are currently several important issues concerning this, particularly regarding which 
patients will benefit from and should be offered adjuvant treatment.
The prognosis of patients with prostate cancer is currently assessed by the TNM staging system after radi-
cal prostatectomy. However, the 5-year BCR-free survival for pT3 patients has been reported to range widely 
(10–66%) according to the presence or absence of a variety of histopathologic, biological, and patient factors7. 
Lymphovascular invasion (LVI) has been demonstrated to be an independent predictor of poor prognosis in 
several solid tumors8–10. Because cancer cells must adhere, penetrate, and migrate into the blood or lymphatic 
vessels before entering circulation11, LVI is believed to be associated with a predisposition for disease recurrence 
or distant metastasis. In a previous study on clinically localized prostate cancer, LVI was demonstrated to be 
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associated with aggressive disease and BCR12,13, although it was concluded that it may not be useful for improving 
the already established predictive models13. Additionally, several small series have reported LVI as an independ-
ent predictor of disease recurrence in patients with pT3 N0 prostate cancer14–16; however, there is still some con-
troversy regarding its prognostic significance in prostate cancer13.
Therefore, the purpose of the current study was to demonstrate the hierarchical relationships between various 
variables, including LVI, for estimating BCR; and to assess the impact of LVI on the risk of BCR in patients with 
pT3 N0 prostate cancer treated with radical prostatectomy.
Results
Baseline Demographics. The baseline characteristics of the 1,210 study patients are presented in Table 1. 
The mean age was 66.2 years, and the mean serum prostate-specific antigen (PSA) level was 15.7 ng/mL. LVI was 
noted in 260 patients (21.5%) and was significantly associated with several other adverse clinicopathologic fea-
tures, such as high preoperative PSA level, large tumor volume, positive surgical margin, seminal vesicle invasion 
(SVI), perineural invasion, and high pathologic Gleason score. Postoperative adjuvant treatment was performed 
in 219 patients (18.1%) as follows: radiation therapy and androgen deprivation therapy (n = 100, 8.3%), radiation 
therapy only (n = 79, 6.5%), and androgen deprivation therapy only (n = 40, 3.3%).
Prognostic Importance of LVI. At a median follow-up of 32.0 months from radical prostatectomy, BCR 
was observed in 352 (29.1%) patients, including 232 (24.4%) patients without LVI and 120 (46.3%) patients with 
LVI (p < 0.001). The 5-year BCR-free survival rates were 60.3% and 32.1% in patients without and with LVI, 
respectively (log rank test, p < 0.001, Fig. 1). When the patients were stratified into 4 groups based on the LVI 
and SVI status, the 5-year BCR-free survival rates were 61.5% in patients without LVI and SVI (n = 752), 54.1% 
in those with SVI only (n = 198), 42.8% in those with LVI only (n = 143), and 22.4% in those with both LVI and 
SVI (n = 117) (log rank test, pooled over strata, p < 0.001, Fig. 1). However, no significant difference in BCR-free 
survival was observed between patients with LVI only and SVI only (log rank test, pairwise over strata, p = 0.745).
In the univariate Cox proportional hazard regression analysis, LVI was significantly associated with an 
increased risk of BCR, and this association remained significant after adjusting for various known prognostic 
factors in the multivariate Cox proportional hazard regression analysis (Table 2).
Graphic structures of the Bayesian belief network analysis are displayed in Fig. 2. Bayesian belief network 
analysis revealed hierarchical associations between the various clinicopathologic features. As shown in Fig. 2, 
there were two first-degree associates of BCR, namely LVI and pathologic Gleason score. Second-degree associ-




LVI (+) LVI (−) p-value
Age (years)* 66.2, 67.0 (± 6.5) 66.4, 67.0 (± 6.1) 66.1, 66.5 (± 6.6) 0.603
BMI (kg/m2)* 24.6, 24.6 (± 2.8) 24.4, 24.2 (± 2.8) 24.7, 24.8 (± 2.8) 0.213
Preoperative PSA (ng/mL)* 15.7, 10.9 (± 17.7) 23.0, 14.8 (± 28.0) 13.6, 9.9 (± 12.9) < 0.001
Total biopsy cores (n)* 11.3, 12.0 (± 1.9) 11.5, 12.0 (± 1.9) 11.2, 12.0 (± 1.9) 0.088
Positive cores (n)* 4.9, 4.0 (± 2.9) 5.6, 6.0 (± 3.2) 4.4, 4.0 (± 2.8) < 0.001
Biopsy Gleason score (%) < 0.001
 ≤ 6 307 (25.4) 33 (12.8) 274 (29.1)
 7 (3+ 4) 321 (26.5) 55 (21.4) 266 (28.2)
 7 (4+ 3) 197 (16.3) 43 (16.7) 154 (16.3)
 ≥ 8 374 (30.9) 126 (49.0) 248 (26.3)
Prostate volume (mL)* 35.5, 33.0 (± 13.9) 37.2, 36.0 (± 14.5) 35.0, 32.4 (± 13.6) 0.025
Tumor volume (%) 0.001
 ≤ 5 mL 568 (46.9) 101 (41.1) 467 (53.3)
 > 5 mL 554 (45.8) 145 (58.9) 409 (46.7)
Extracapsular extension (%) 1179 (97.4) 251 (96.5) 928 (97.8) 0.251
Seminal vesicle invasion (%) 297 (24.5) 118 (45.4) 178 (18.8) < 0.001
Positive surgical margin (%) 716 (59.2) 171 (65.8) 544 (57.3) 0.014
Perineural invasion (%) 1103 (91.2) 250 (96.2) 853 (89.9) 0.002
Pathologic Gleason score (%) < 0.001
 ≤ 6 85 (7.0) 4 (1.5) 81 (8.6)
 7 (3+ 4) 452 (37.4) 52 (20.1) 400 (42.2)
 7 (4+ 3) 350 (28.9) 95 (36.7) 255 (26.9)
 ≥ 8 320 (26.4) 108 (41.7) 211 (22.3)
Table 1.  Baseline demographics of the patients. *Values are expressed as mean, median (± SD) LVI, 
lymphovascular invasion; BMI, body mass index; PSA, prostate-specific antigen.
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Figure 3 shows the relative importance of each clinicopathologic feature to BCR based on the random survival 
forest analysis. The prediction model of random survival forest had the accuracy (C-index) of 0.76 ± 0.0005. 
Pathologic Gleason score (1.0), LVI (0.2836), and preoperative PSA level (0.1502) were found to be the three 
most important clinicopathologic factors in determining the risk of BCR in the patients with pT3 N0 prostate 
cancer. Conversely, the relative importance of SVI and positive surgical margin was only 0.0102 and − 0.0248, 
respectively.
Discussion
In the present study, LVI was identified in 21.5% of patients with pT3 N0 prostate cancer after radical prostatec-
tomy. Additionally, LVI was also found to be associated with several adverse clinicopathologic features and poor 
BCR-free survival. However, there appear to be substantial inconsistencies regarding the association between LVI 
and BCR after radical prostatectomy in the literature. Ng and colleagues performed a systematic review in this 
subject and reported that only 58% of the included studies found that LVI was as an independent predictor of 
BCR with odds ratios or relative risks of 1.39–4.3917. However, many of these previous studies included patients 
Figure 1. (a) BCR-free survival according to LVI in the K-CaP cohort (p < 0.001). (b) BCR-free survival 
according to LVI and SVI in the K-CaP cohort (p < 0.001).
Factors
Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age (years) 1.009 0.992–1.025 0.313 1.000 0.982–1.018 0.982
BMI (kg/m2) 0.972 0.936–1.011 0.154 0.965 0.925–1.006 0.090
Preoperative PSA (ng/mL) 1.022 1.009–1.036 < 0.001 1.013 1.008–1.216 0.018
Prostate volume (mL) 1.004 0.996–1.012 0.311 0.997 0.987–1.006 0.484
Tumor volume (> 5mL) 1.912 1.530–2.391 < 0.001 1.506 1.191–1.903 0.001
Extracapsular extension 0.943 0.517–1.720 0.847 1.378 0.709–2.679 0.345
Seminal vesicle invasion 2.348 1.890–2.917 < 0.001 1.588 1.245–2.026 < 0.001
Positive surgical margin 1.659 1.323–2.081 < 0.001 1.171 0.913–1.500 0.214
Lymphovascular invasion 2.038 1.635–2.541 < 0.001 1.357 1.064–1.730 0.014
Perineural invasion 1.392 1.002–1.684 0.023 1.278 1.039–1.896 0.230
Pathologic Gleason score
 ≤ 6 Reference Reference
 7 (3+ 4) 1.080 0.631–1.849 0.778 1.041 0.575–1.881 0.895
 7 (4+ 3) 2.087 1.229–3.546 0.006 1.731 1.001–3.119 0.048
 ≥ 8 4.247 2.528–7.137 < 0.001 3.127 1.744–5.606 < 0.001
Adjuvant treatment 2.301 1.216–3.482 0.002 1.562 0.913–2.896 0.231
Table 2.  Univariate and multivariate Cox proportional hazard regression analysis of clinicopathologic 
features for biochemical recurrence. HR, hazard ratio; CI, confidence interval; BMI, body mass index; PSA, 
prostate-specific antigen.
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with pathologically organ-confined prostate cancer (pT2 N0), which, due to the relatively low incidence of LVI 
and BCR in this population, may have resulted in bias. On the other hand, Yamamoto et al.16 reported that LVI 
was a significant predictor of BCR in 94 patients with pT3a N0 prostate cancer. Similarly, You et al.18 analyzed the 
prognostic factors of 397 patients with pathologic stage T3–T4 N0 disease and reported that LVI was observed 
in 18.6% of the patients and was an independent predicting factor of BCR in T3a disease. These results are in 
keeping with our results. However, in contrast to the present study, none of these prior studies have added LVI to 
the risk stratification for BCR.
There are a number of challenges in identifying LVI in prostatectomy specimens. Overdiagnosis due to mim-
ickers is important challenges relating to the diagnosis of LVI in prostate cancer. Kryvenko et al.19 reported that 
retraction artifact, pseudoembolus, and ingrowth of myofibroblasts into large extraprostatic vessels are common 
mimickers of LVI. They also reported that there were some cases with LVI that were missed on routine hematox-
ylin and eosin sections. Although there might be several challenges and interobserver variability, LVI in prosta-
tectomy specimens has been reported widely by experienced uropathologist. The International Collaboration on 
Cancer Reporting developed structured protocols for radical prostatectomy specimens, and considered that LVI 
should be listed as a recommended element20. They mentioned that diagnosis of LVI on hematoxylin and eosin 
sections is reliable, and immunohistochemical staining is rarely recommended.
Herein, we confirmed the prognostic significance of LVI in pT3 N0 prostate cancer using three different sta-
tistical methods. First, multivariate Cox proportional hazard regression analysis was performed to model the 
relationship between BCR-free survival and the different covariates. In the multivariate Cox proportional hazard 
regression analysis, several covariates, including LVI and SVI, were identified as independent predicting factors 
for BCR. However, the Cox proportional hazard regression analysis is not adept at assessing the relative impor-
tance of these factors or for discovery of potential interactions. Thus, to confirm the results of the Cox model and 
Figure 2. Bayesian belief network analysis for biochemical recurrence in the K-CaP cohort. PSA, prostate-
specific antigen; LN, lymph node; LV, lymphovascular; pGleason, pathologic Gleason score; PIN, prostatic 
intraepithelial neoplasia; SV, seminal vesicle; PN, perineural.
Figure 3. Relative importance of each clinicopathologic variable for BCR based on random survival forest 
analysis in the K-CaP cohort. PSA, prostate-specific antigen; LN, lymph node; BMI, body mass index.
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to assess the relationships between variables unexplained by this model, Bayesian belief network and random 
survival forest analyses were performed. These analyses were chosen for a variety of reasons. First, the random 
survival forest analysis is known to address the problems of restrictive assumption, such as the proportional 
hazards, of the Cox model21. Second, the random survival forest analysis has the advantages of intuitive compari-
sons of predictive importance between variables, and adjustment for potential multiple interactions in estimating 
importance21. Finally, the Bayesian belief network analysis provides a method for representing causal probabil-
istic relationships between variables by its graphical nature22. This allows the physicians or researchers to better 
understand the hierarchy and relative importance of each variable. In our study, all of the above statistical meth-
ods found that LVI was one of the most important risk factors for BCR in patients with pT3 N0 prostate cancer.
In our study, the impact of positive surgical margin on BCR failed to reach statistical significance in the 
multivariate Cox proportional hazard regression and random survival forest analyses. Many prior studies have 
reported that positive surgical margin is an independent predictive factor of BCR after radical prostatectomy, 
and it is considered as one of the most important factors to determine adjuvant treatment23. These discordances 
between the present and prior studies might have been caused by inclusion of patients with SVI in our study 
cohort. Several studies have reported that positive surgical margin is an independent factor in pT2 and T3a pros-
tate cancer, but not in pT3b cancer24,25. Hence, we speculate that LVI, which is a pathologic variable reflecting 
potential for micrometastasis, is perhaps more important than positive surgical margin, which might be depend-
ent on the local extent of the disease, in locally advanced cancers.
Our study has several important strengths and weaknesses. This is the non-randomized, retrospective study, 
which inherently associated with selection bias. Also, several pathologists from different institutes were involved 
during the study period without central pathology review. Nonetheless, it has the strengths of including a large 
number of pT3 N0 prostate cancer patients retrieved from the K-CaP database, an observational longitudinal 
multicenter database of Korean prostate cancer patients. Moreover, our study also suggested a possible prognostic 
role of LVI in pT3 N0 prostate cancer through novel statistical analysis. These novel statistical analytic methods 
could rectify several shortcomings of the traditional Cox proportional hazard regression analysis and provide 
evidence for the prognostic importance of LVI. The inclusion of LVI as a prognostic factor may improve the abil-
ity to inform pT3 N0 prostate cancer patients about their prognosis, and could be used to guide the decision for 
postoperative management in this population through the proper stratification of patients.
Methods
K-CaP Database Construction. Clinical information was extracted from the K-CaP database, an obser-
vational longitudinal database of Korean patients with biopsy-proven prostate cancer enrolled from 5 hospitals 
throughout Korea. Details regarding the K-CaP database have been previously reported26. The K-CaP database 
system provides 220 items for prostate cancer research; demographics, medical history, clinical information, 
pathologic results, follow-up data, and so on27.
Eligible Patients and Outcomes. A total of 1,622 patients with pT3 N0 prostate cancer treated with rad-
ical prostatectomy between 2001 and 2012 were identified. To ensure a uniform population for evaluating the 
pathologic findings, patients were excluded if they received neoadjuvant androgen deprivation therapy (n = 325, 
20.0%) or if they did not have sufficient pathologic or follow-up data (n = 87, 5.4%), resulting in a total of 1,210 
patients being included in this study. LVI was defined as the presence of cancer cells within an arterial, venous, 
or lymphatic lumen on routine hematoxylin and eosin sections. The primary endpoint was to assess the onco-
logic importance of LVI on the risk of BCR in patients with pT3 N0 prostate cancer. The secondary endpoint 
was to determine the hierarchical relationships between variables for estimating BCR. Clinical outcome meas-
ures included age, body mass index, serum PSA level, biopsy Gleason score, clinical stage, pathologic Gleason 
score, pathologic stage, various pathologic outcomes, adjuvant treatment, and BCR. BCR was defined as a serum 
PSA level ≥ 0.2 ng/ml on two consecutive measurements or administration of salvage treatment for a persis-
tently rising serum PSA level. The study protocol was approved and carried out in accordance with the approved 
guidelines by the Institutional Review Board at the Catholic University of Korea, Seoul St. Mary’s Hospital (IRB 
approval No. KC14RIMI0676).
Statistical Analysis. Statistical analysis was performed using IBM SPSS software, version 19.0 (SPSS, Inc., 
Chicago, Illinois, USA) and R-3.1.1 software (R Project for Statistical Computing, http://www.r-project.org/). To 
account for missing values in the training dataset, we imputed missing values using the random survival forest 
method. The missing values were inferred as weighted averages based on proximity between patients, which is 
the likelihood that patients are in the same leaf node of the survival trees. Continuous variables are presented 
as mean or median value (± standard deviation [SD]) and categorical variables are presented as proportions. 
Differences in the clinicopathologic features were examined using the independent t-test and chi-square test for 
continuous and categorical variables, respectively. BCR-free survival was estimated using Kaplan-Meier analysis 
and compared using the log rank test. The association between LVI and BCR was assessed using multivariate Cox 
proportional hazard regression analysis in a forward stepwise regression after adjusting for known important 
clinicopathologic features. Biopsy Gleason score and number of positive cores were excluded in advance due to 
the high correlations between biopsy and pathology Gleason score, and between the number of positive cores and 
tumor volume (0.64 and 0.33, respectively).
Bayesian Belief Network Analysis. We used Bayesian belief network to derive the hierarchical causal 
relationships between BCR and predictor variables. The Bayesian belief network is a statistical graphic model 
that represents conditional probabilistic relationships between variables. Each node in the network represents a 
feature, and an edge between the nodes represents a causal dependency. If two nodes have an edge, then we can 
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infer that the two variables have a probabilistic relationship and are more likely to occur together, thus we can 
identify which variables affect BCR. We learned the structure of the Bayesian belief network by hill-climbing 
score function using the bnlearn R package28.
Random Survival Forest Analysis. The random survival forest is an ensemble tree method for analysis of 
right-censored survival data21. This method constructs multiple decision trees based on bootstrap data and pre-
dicts the outcome of interest (i.e. BCR) based on the majority votes of the individual decision trees. To discover 
which variables are the key prognostic factors to predict BCR, we ranked prognostic abilities of variables using 
variable importance scores. The variable importance score is defined as the increase in prediction error if the 
variable is randomized, providing insight into how predictive the variable is. To evaluate accuracy of the random 
survival forest, we used bootstrap validation with 1000 bootstraps29. We developed the decision trees and its 
importance score using training set, and validate them using test set. Training sets were randomly selected from 
63.2% of patients with replacement, and test sets were un-selected (36.8% of patients), and repeated it 1000 times. 
This validation method has proven to be an unbiased estimate of prediction error30. The random survival forest 
was developed using the R package RandomSurvivalForest21.
Conclusions
Our analysis of the clinicopathologic features of patients with pT3 N0 prostate cancer treated with radical prosta-
tectomy provides evidence that LVI is one of the most powerful adverse pathologic prognostic factors of patients 
with pT3 N0 prostate cancer treated with radical prostatectomy. LVI status can provide clinically important prog-
nostic information, which may aid in the decision of the postoperative management for patients with pT3 N0 
prostate cancer through the proper stratification of patients, and we accordingly advocate incorporating LVI 
status into the present prostate cancer staging systems.
References
1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11–30, doi: 10.3322/caac.21166 (2013).
2. Moul, J. W. et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate 
Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 166, 1322–1327, doi: 10.1016/
S0022-5347(05)65761-8 (2001).
3. Sooriakumaran, P. et al. Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with 
a minimum follow-up time of 5 years. Eur Urol 62, 768–774, doi: 10.1016/j.eururo.2012.05.024 (2012).
4. Amling, C. L. et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued 
risk of biochemical failure after 5 years. J Urol 164, 101–105, doi: 10.1016/S0022-5347(05)67457-5 (2000).
5. Thompson, I. M. Jr. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 
2329–2335, doi: 10.1001/jama.296.19.2329 (2006).
6. Van der Kwast, T. H. et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: 
EORTC 22911. J Clin Oncol 25, 4178–4186, doi: 10.1200/JCO.2006.10.4067 (2007).
7. Swanson, G. P., Riggs, M. & Hermans, M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 
25, 110–114, doi: 10.1016/j.urolonc.2006.06.003 (2007).
8. Rakha, E. A. et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 118, 3670–3680, doi: 
10.1002/cncr.26711 (2012).
9. Lim, S. B. et al. Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum 53, 377–384, doi: 
10.1007/DCR.0b013e3181cf8ae5 (2010).
10. Kikuchi, E. et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial 
carcinoma. J Clin Oncol 27, 612–618, doi: 10.1200/JCO.2008.17.2361 (2009).
11. Ribatti, D., Mangialardi, G. & Vacca, A. Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination. Clin Exp Med 6, 
145–149, doi: 10.1007/s10238-006-0117-4 (2006).
12. Mitsuzuka, K. et al. Lymphovascular invasion is significantly associated with biochemical relapse after radical prostatectomy even 
in patients with pT2N0 negative resection margin. Prostate Cancer Prostatic Dis 18, 25–30 doi: 10.1038/pcan.2014.40 (2015).
13. Yee, D. S. et al. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU Int 108, 502–507, doi: 
10.1111/j.1464-410X.2010.09848.x (2011).
14. Epstein, J. I., Partin, A. W., Potter, S. R. & Walsh, P. C. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic 
stratification based on pathologic parameters. Urology 56, 283–288, doi: 10.1016/S0090-4295(00)00640-3 (2000).
15. Herman, C. M., Wilcox, G. E., Kattan, M. W., Scardino, P. T. & Wheeler, T. M. Lymphovascular invasion as a predictor of disease 
progression in prostate cancer. Am J Surg Pathol 24, 859–863, doi: 10.1097/00000478-200006000-00012 (2000).
16. Yamamoto, S. et al. Lymphovascular invasion is an independent predictor of prostate-specific antigen failure after radical 
prostatectomy in patients with pT3aN0 prostate cancer. Int J Urol 15, 895–899, doi: 10.1111/j.1442-2042.2008.02140.x (2008).
17. Ng, J., Mahmud, A., Bass, B. & Brundage, M. Prognostic significance of lymphovascular invasion in radical prostatectomy 
specimens. BJU Int 110, 1507–1514, doi: 10.1111/j.1464-410X.2012.11115.x (2012).
18. You, D. et al. High percent tumor volume predicts biochemical recurrence after radical prostatectomy in pathological stage T3a 
prostate cancer with a negative surgical margin. Int J Urol 21, 484–489, doi: 10.1111/iju.12348 (2014).
19. Kryvenko, O. N. & Epstein, J. I. Histologic criteria and pitfalls in the diagnosis of lymphovascular invasion in radical prostatectomy 
specimens. Am J Surg Pathol 36, 1865–1873, doi: 10.1097/PAS.0b013e318262c3d0 (2012).
20. Kench, J. G. et al. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the 
International Collaboration on Cancer Reporting. Histopathology 62, 203–218, doi: 10.1111/his.12042 (2013).
21. Ishwaran, H., Kogalur, U. B., Blackstone, E. H. & Lauer, M. S. Random survival forests. Ann Appl Stat 2, 841–860, doi: 10.1214/08-
AOAS169 (2008).
22. Uusitalo, L. Advantages and challenges of Bayesian networks in environmental modelling. Ecol Model 203, 312–318, doi: 10.1016/j.
ecol model.2006.11.033 (2007).
23. D’Amico, A. V. et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after 
radical prostatectomy for prostate cancer. J Urol 154, 131–138, doi: 10.1016/S0022-5347(01)67248-3 (1995).
24. Ohori, M., Wheeler, T. M., Kattan, M. W., Goto, Y. & Scardino, P. T. Prognostic significance of positive surgical margins in radical 
prostatectomy specimens. J Urol 154, 1818–1824, doi: 10.1016/S0022-5347(01)66792-2 (1995).
25. Ploussard, G. et al. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant 
treatment-naive patients. BJU Int 107, 1748–1754, doi: 10.1111/j.1464-410X.2010.09728.x (2011).
26. Lee, D. H. et al. The Establishment of K-CaP (the Multicenter Korean Prostate Cancer Database). Korean J Urol 54, 229–233, doi: 
10.4111/kju.2013.54.4.229 (2013).
www.nature.com/scientificreports/
7Scientific RepoRts | 6:25419 | DOI: 10.1038/srep25419
27. Choi, I. Y. et al. Development of prostate cancer research database with the clinical data warehouse technology for direct linkage 
with electronic medical record system. Prostate Int 1, 59–64, doi: 10.12954/PI.12015 (2013).
28. Scutari, M. Learning Bayesian networks with the bnlearn R package. J Stat Softw 35, 1–22, doi: 10.18637/jss.v035.i03 (2010).
29. Kohavi, R. A study of cross-validation and bootstrap for accuracy estimation and model selection. In: Ijcai 2, 1137–1145 (1995).
30. Breiman, L. Random forests. Mach Learn 45, 5–32, doi: 10.1023/A:1010933404324 (2001).
Acknowledgements
This work was supported by the Korean Prostate Bank supported by the National Research Foundation funded by 
the Ministry of Science, ICT and Future Planning, Korea (NRF-2012M3A9B8021691).
Author Contributions
Y.H.P. and J.Y.L. designed this study and prepared the manuscript. S.S.B., C.K., B.H.C., H.M.L., C.S.K. and J.Y.L. 
collected and analyzed the clinical data. Y.H.P., Y.K., I.Y.C. and H.Y. performed statistical analysis. All authors 
reviewed the manuscript.
Additional Information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Park, Y. H. et al. Is lymphovascular invasion a powerful predictor for biochemical 
recurrence in pT3 N0 prostate cancer? Results from the K-CaP database. Sci. Rep. 6, 25419; doi: 10.1038/
srep25419 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
